<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1458">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358939</url>
  </required_header>
  <id_info>
    <org_study_id>HIGH-PRONE-COVID-19</org_study_id>
    <secondary_id>2020-A01121-38</secondary_id>
    <secondary_id>DR200125</secondary_id>
    <nct_id>NCT04358939</nct_id>
  </id_info>
  <brief_title>Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19)</brief_title>
  <official_title>Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Respiratory Distress Syndrome (ARDS) induces high mortality, particularly in the
      context of COVID-19 disease. Preliminary data from patients with ARDS related to COVID-19
      disease appear to show significant effectiveness of prone positioning in intubated patients
      in terms of oxygenation as well as nasal high flow therapy before intubation. It should be
      noted that in Jiangsu province, secondarily affected, nasal high flow combined with the prone
      position was successfully integrated into care protocols.

      The investigators hypothesize that the combined application of nasal high flow and prone
      positioning can significantly improve the outcome of patients suffering from COVID-19
      pneumonia by reducing the need for tracheal intubation and associated therapeutics such as
      sedation and paralysis, resulting in both individual and collective benefits in terms of use
      of scarce critical care resources.

      Investigators hypothesize that the combined application of nasal high-flow and prone
      positioning can significantly improve the outcome of patients suffering from COVID-19
      pneumonia by reducing the need for intubation and associated therapeutics such as sedation
      and paralysis, resulting in both individual and collective benefits in terms of use of scarce
      critical care resources.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute Respiratory Distress Syndrome (ARDS) induces high mortality, particularly in the
      context of COVID-19 disease. In patients with ARDS who are mechanically ventilated invasively
      through a tracheal tube and with a PaO2/FiO2 ratio (arterial oxygen partial pressure to
      inspired oxygen fraction ratio) of less than 150 mmHg, prone positioning significantly
      reduced mortality. Furthermore, nasal high flow, a non-invasive respiratory support and
      oxygenation technique, reduced the need for tracheal intubation and reduced mortality among
      the most severe patients (PaO2/FiO2 ratio less than 200 mmHg) suffering from acute hypoxemic
      respiratory failure. Prone positioning of ARDS patients treated with nasal high-flow was
      evaluated in 20 patients with predominantly viral pneumonia. The prone positioning was found
      to be feasible and associated with an increased PaO2/FiO2 ratio. Preliminary data from
      patients with ARDS related to COVID-19 disease appear to show a significant effect of prone
      positioning in intubated patients in terms of oxygenation improvement as well as nasal
      high-high flow appears effective in non-intubated patients. For instance, nearly half
      intensive care unit patients described in the princeps cohort in Wuhan City, Hubei Province,
      China, had received nasal high-flow. It should be noted that in Jiangsu province, secondarily
      affected, nasal high-flow combined with prone positioning was successfully integrated into
      care protocols.

      Investigators hypothesize that the combined application of nasal high-flow and prone
      positioning can significantly improve the outcome of patients suffering from COVID-19
      pneumonia by reducing the need for intubation and associated therapeutics such as sedation
      and paralysis, resulting in both individual and collective benefits in terms of use of scarce
      critical care resources.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">November 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic failure within 14 days of randomization</measure>
    <time_frame>From randomization to day 14</time_frame>
    <description>Therapeutic failure is defined by death or intubation or use of non-invasive ventilation at two pressure levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic failure within 28 days of randomization</measure>
    <time_frame>From randomization to day 28</time_frame>
    <description>Therapeutic failure is defined by death or intubation or use of non-invasive ventilation at two pressure levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timeframe of intubation or death</measure>
    <time_frame>From randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timeframe of therapeutic escalation (in case of non-invasive ventilation at two pressure levels)</measure>
    <time_frame>From randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of oxygenation (PaO2/FiO2 ratio or SpO2/FiO2 surrogate) over the 14 days following randomization</measure>
    <time_frame>From randomization to day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the SpO2/FiO2 ratio during the first prone session</measure>
    <time_frame>From randomization to day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the ROX index during the first prone session</measure>
    <time_frame>From randomization to day 1</time_frame>
    <description>ROX index is the ratio of pulse oximetry (SpO2)/fraction of inspired oxygen (FiO2) to respiratory rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the World Health Organization disease severity score of COVID</measure>
    <time_frame>From randomization to day 28</time_frame>
    <description>Score reaches from 1 to 7, 7 indicates worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient comfort before, during and after the first prone position session</measure>
    <time_frame>From randomization to day 1</time_frame>
    <description>Comfort evaluted by the patient through a visual analogical scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of skin lesions on the anterior surface of the body</measure>
    <time_frame>From randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Displacement of invasive devices during reversals</measure>
    <time_frame>From randomization to day 28</time_frame>
    <description>Invasive devices include : central and peripheric vascular catheters, tracheal tube, urinary catheter, chest tubes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of nasal High-Flow therapy use in the general population, in non-intubated patients and in intubated patients</measure>
    <time_frame>From randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days spent in the intensive care unit and in the hospital</measure>
    <time_frame>From randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in the intensive care unit and in the hospital</measure>
    <time_frame>From randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free-days within 28 days of randomization</measure>
    <time_frame>From randomization to day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Prone decubitus group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prone positioning of patients on nasal high-flow oxygen therapy with usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients on nasal high-flow oxygen therapy with usual care and positioned in supine</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prone decubitus</intervention_name>
    <description>According to the tolerance, the objective is to spend as much time as possible, up to 16 hours and beyond in prone position every 24 hours. At least two sessions of at least 30 minutes each must be performed daily.</description>
    <arm_group_label>Prone decubitus group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient

          -  with COVID-19 pneumonia according to the diagnostic criteria in effect at the time of
             inclusion or very highly suspected.

          -  Patient treated with nasal high-flow

          -  Mild, moderate or severe ARDS: bilateral radiological opacities not fully explained by
             effusions, atelectasis or nodules; acute hypoxemia with worsening within the previous
             7 days, not fully explained by left ventricular failure; PaO2/FiO2 ratio &lt; 300 mmHg
             (or equivalent SpO2/FiO2).

          -  Covered by or having the rights to French social security

          -  Informed Consent

        Exclusion Criteria:

        Pregnant or breastfeeding woman

          -  Indication for immediate tracheal intubation

          -  Progressive significant acute circulatory insufficiency

          -  Impaired alertness, confusion, restlessness

          -  Body mass index &gt; 40 kg/m2

          -  Thoracic trauma or other contraindication to prone position

          -  Pneumothorax with single anterior thoracic drain and persistent bubbling

          -  Vulnerable person: safeguard of justice, guardianship or authorship known at inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yonatan PEREZ, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yonatan PEREZ, MD</last_name>
    <phone>(0)2.47.47.38.55</phone>
    <phone_ext>+33</phone_ext>
    <email>y.perez@chu-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan EHRMANN, MD-PhD</last_name>
    <phone>(0)2.47.47.98.51</phone>
    <phone_ext>+33</phone_ext>
    <email>stephan.ehrmann@univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intensive Care Unit, University Hospital, Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent LEFEBVRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent LEFEBVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien MAIZEL, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Julien MAIZEL, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital, Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaetan PLANTEFEVE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gaetan PLANTEFEVE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier GRUSON, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Didier GRUSON, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaël PRAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gwenaël PRAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, Hospital, Béthune</name>
      <address>
        <city>Béthune</city>
        <zip>62408</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe VINSONNEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe VINSONNEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélie JORET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélie JORET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Louis Mourier-APHP</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien ROUX, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Damien ROUX, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital, Dax</name>
      <address>
        <city>Dax</city>
        <zip>40107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrien AUVET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adrien AUVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre QUENOT, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre QUENOT, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas TERZI, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas TERZI, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital, Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe GUITTON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe GUITTON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, University Hospital, Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saadalla NSEIR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Saadalla NSEIR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, Hospital, Mont-de-Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud SEMENT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud SEMENT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean REIGNIER, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean REIGNIER, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Nice</name>
      <address>
        <city>NIce</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean DELLAMONICA, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean DELLAMONICA, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, Hospital, Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mai-Anh NAY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mai-Anh NAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, Tenon-APHP</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume VOIRIOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume VOIRIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud THILLE, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud THILLE, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yonatan PEREZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yoanatan PEREZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan EHRMANN, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Surgical Intensive Care Unit, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Charlotte TELLIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne-Charlotte TELLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, University Hospital, Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno LEVY, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Bruno LEVY, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital, Vannes</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agathe DELBOVE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Agathe DELBOVE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Nasal High-Flow</keyword>
  <keyword>Prone position</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data after de-identification can be obtained by contacting the corresponding author.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available immediately following publication and ending in 5 years.</ipd_time_frame>
    <ipd_access_criteria>Contact with the corresponding author.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

